Physician profile
Anthony Hiffa
NPI 1831671536
$8,485.70
in general payments reported to CMS, 2019-2025
34 companies · $3,592 in 2025
The $3,592 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $88.52 · 2024: $4,805 · 2025: $3,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,398 · Travel and Lodging: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,398.06 |
| Travel and Lodging | $2,145.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,898.63 | 2024-2025 | Altaviva, Interstim |
| Coloplast Corp | $1,121.63 | 2024-2025 | |
| Siemens Medical Solutions USA, INC. | $883.02 | 2024 | |
| Teleflex LLC | $674.32 | 2024-2025 | Barrigel, Urolift |
| Procept Biorobotics Corporation | $335.92 | 2024-2025 | Aquabeam System |
| Boston Scientific Corporation | $276.96 | 2024-2025 | Axonics, Ams 700, Greenlight Xps |
| Axonics, INC. | $268.92 | 2024 | Axonics, Bulkamid |
| Cook Medical LLC | $262.70 | 2024 | Litho 150 |
| Angiodynamics, INC. | $193.16 | 2025 | Nanoknife |
| Sumitomo Pharma America, INC. | $163.69 | 2024-2025 | Orgovyx |
| Olympus America INC. | $148.91 | 2024-2025 | Itind System, Soltive |
| Merck Sharp & Dohme LLC | $129.83 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Tempus Ai, INC | $112.74 | 2024-2025 | Xt Cdx |
| Conmed Corporation | $109.82 | 2024 | Abc Handpieces, Airseal, Conmed Specimen Retrieval |
| Astellas Pharma US INC | $101.94 | 2025 | Xtandi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $95.84 | 2024-2025 | Eligard, Jatenzo |
| Urogen Pharma, INC. | $92.99 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $76.09 | 2024 | Xiaflex |
| Calyxo, INC. | $74.31 | 2024-2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $71.43 | 2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $60.63 | 2024-2025 | Provenge |
| Antares Pharma, INC. | $52.52 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $48.95 | 2025 | |
| Ferring Pharmaceuticals INC. | $46.49 | 2025 | Adstiladrin |
| Janssen Scientific Affairs, LLC | $42.43 | 2024 | Erleada |
| Baxter Healthcare | $26.77 | 2025 | Tisseel |
| Myriad Genetic Laboratories, INC. | $25.65 | 2024 | Prolaris |
| Laborie Medical Technologies Corp. | $25.32 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Verity Pharmaceuticals INC. | $24.43 | 2025 | Tlando |
| Novartis Pharmaceuticals Corporation | $22.50 | 2025 | |
| Ethicon US, LLC | $20.95 | 2025 | Vistaseal |
| Vertex Pharmaceuticals Incorporated | $19.66 | 2025 | |
| Civco Medical Instruments | $17.41 | 2025 | |
| Immunitybio, INC. | $17.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Hiffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.